

## Product datasheet for **TL303636V**

### KRAS Human shRNA Lentiviral Particle (Locus ID 3845)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	KRAS Human shRNA Lentiviral Particle (Locus ID 3845)
Locus ID:	3845
Synonyms:	C-K-RAS; c-Ki-ras2; CFC2; K-Ras; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS; NS3; RALD; RASK2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	KRAS - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, $>10^7$ TU/ml.
RefSeq:	<a href="#">NM_004985</a> , <a href="#">NM_033360</a> , <a href="#">NM_004985.1</a> , <a href="#">NM_004985.2</a> , <a href="#">NM_004985.3</a> , <a href="#">NM_004985.4</a> , <a href="#">NM_033360.1</a> , <a href="#">NM_033360.2</a> , <a href="#">BC013572</a> , <a href="#">BC013572.2</a> , <a href="#">BC010502</a> , <a href="#">BC029545</a> , <a href="#">NM_001369786</a> , <a href="#">NM_001369787</a> , <a href="#">NM_033360.4</a> , <a href="#">NM_004985.5</a>
UniProt ID:	<a href="#">P01116</a>
Summary:	This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).